Truven.biz

COmpARATIVE EFFECTIVENESS
RESEARCH
OUR SOLUTION
offer the largest convenience sample available in proprietary databases great potential for improving healthcare hard evidence to inform choices. The Truven Health AnalyticsSM MarketScan® Retrospective Analyses of
Outcomes
longitudinal, patient-level analyses of health and economic outcomes. Comprehensive Data to Support
Comparative Effectiveness Studies
different options that are available for treating a particular medical condition, § Cost effectiveness of drugs and other § Effectiveness of brand versus generic Specific patient population Studies
Figure 1: Age Comparison
Evaluation of Treatment
Featured peer-Reviewed
Effectiveness Over Time
publications
physician office visits, hospitalizations, of these data sources allows researchers on treatment effectiveness over time. On behalf of the Assistant Secretary for Planning and Evaluation (ASPE), Truven Health is creating Web-based tools to facilitate comparative effectiveness research using multiple databases, including MarketScan data.
Amin AN, Lin J, Johnson BH,
Schulman KL. Clinical and economic
2009; Nov 18; [Epub ahead of print].
Current Medical Research and Opinion 2008 Aug; 24(8): 2203-17. [Cohen Amin AN, Lin J, Lenhart G,
Schulman KL. Clinical and
risk of venous thromboembolism receiving appropriate enoxaparin or surgical patients. Health Services Research 2008; 43(6): 2067–85. Barr CE, Schulman K, Iacuzio D,
Bradley JS. Effect of oseltamivir on
Krupski TL, Foley KA, Baser O, Long
S, Macarios D, Litwin MS. Healthcare
Brixner DI, Lenhart G, Young DC,
Chu E, Schulman KL, Zelt S, Song X.
Mark TL, Gibson T, McGuigan K. The
effects of antihypertensive step-therapy Citrome L, Reist C, Palmer L,
Montejano LB, Lenhart G, Cuffel B,
T, Mark TL, Del Valle M. Comparison
Rugo HS, Kohles J, Schulman KL. Cost
Wish JB, Nassar GM, Schulman K, del
patients with chronic kidney disease. Clinical Nephrology 2008; 69(4): 251–9.
Song X, Long SR, Marder WD,
Sullivan SD, Kallich J. The impact
of methodological approach on cost
findings in comparison of epoetin
alfa with darbepoetin alfa. Annals of
Pharmacotherapy 2009; 43(7): 1203–10.
Wang MT, Skrepnek GH, Armstrong E, Sherrill DL, Harris RB, Tsai CL, Malone DC. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Current Medical Research and Opinion 2008; 24(3): 859–67.
FOR mORE INFORmATION
To learn how our research and
information solutions can support
your comparative effectiveness
analyses, please contact
us at +1 866 301 5419 or
[email protected].
ABOUT TRUVEN HEALTH ANALYTICS
Truven Health Analytics delivers unbiased information, analytic tools, benchmarks, and services to the healthcare industry. Hospitals, government agencies, employers, health plans, clinicians, pharmaceutical, and medical device companies have relied on us for more than 30 years. We combine our deep clinical, financial, and healthcare management expertise with innovative technology platforms and information assets to make healthcare better by collaborating with our customers to uncover and realize opportunities for improving quality, efficiency, and outcomes. With more than 2,000 employees globally, we have major offices in Ann Arbor, Mich.; Chicago; and Denver. Advantage Suite, Micromedex, ActionOI, MarketScan, and 100 Top Hospitals are registered trademarks or trademarks of Truven Health Analytics.
truvenhealth.com | 1.800.525.90832012 Truven Health Analytics Inc. All rights reserved. All other product names used herein are trademarks of their respective owners. ACRS 11228 0912

Source: http://www.truven.biz/assets/ACRS_11228_0912_CompEffectResearch_SS_Web.pdf